Loading...

XOMA XOMA ROYALTY CORP Contract Awards 8-K Filing

XM R

XM

XOMA ROYALTY CORP

(XOMA)

2024 8-K

Show Summary

Show Summary

Change of Jurisdiction

Financial Statements

Financial Results

Acquisition Update

Merger Announcement

Q3 Financial Results

Royalty Purchase

Q2 2024 Results

Acquisition of Kinnate Biop...

Sale of Priority Review Vou...

Annual Meeting of Stockholders

Financial Results Announcement

Completion of Acquisition

Merger Agreement

Appointment of CEO

Loan Agreement with Blue Ow...

Financial Results Announcement

Termination of License Agre...

Payment Received

Financial Results Announcement

Product Discontinuation

Acquisition of Assets and R...

Annual Meeting Approval

Financial Results Announcement

Acquisitions and mergers

Financial Results Announcement

Appointment of Owen Hughes ...

External Links:

XOMA Royalty Corporation announced that Zevra Therapeutics received FDA approval for MIPLYFFA, a treatment for Niemann-Pick disease, and XOMA has a royalty agreement that includes a $5 million upfront payment and potential milestone payments of up to

AI Assistant

XOMA ROYALTY CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.